Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA), A Pilot Study

Status unconfirmed

Conditions studied: Psoriatic Arthritis

In brief

Objectives: To identify a candidate set of biomarkers specific to AxPsA. Overview: Clinical and imaging characterization of PsA patients will be combined with extensive molecular assessment of both liquid and tissue compartments to identify biomarkers which differentiate PsA patients with and without axial involvement

Key facts

Study ID

NCT05925842

Run by

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis

People needed

40

Starts

2023-01-25

Expected to finish

2024-09-01

Last updated by the study team

2023-06-29

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Persons with PsA diagnosed by a consultant Rheumatologist with disease duration of > 3 months but < 10 years with or without IBP.
• Adults between the ages 18 and 80 years, with joint disease onset after 16 years of age
• Patients able to understand and complete consent procedures
• Study participants must have PsA, meet CASPAR criteria, and must have active disease as defined by the treating rheumatologist, including an evaluable psoriatic skin lesion amenable to 6mm punch skin biopsy.
• o Psoriasis should be diagnosed by a consultant rheumatologist or dermatologist.
• Study participants must have been on consistent therapy for their PsA for the past 90 days
• Study participants must be naïve to biological treatment and targeted synthetic DMARD treatment (examples: JAK inhibitors, apremilast)

You may not qualify if…

• • Persons with musculoskeletal (peripheral or axial) symptoms for >10 years
• Persons with planned major surgery (e.g., joint replacement) within the duration of the collection of data for the study
• Persons with a history of chemotherapy, radiation therapy or immunotherapy for cancer in the preceding 5 years.
• Persons with ongoing cancer (not excluding non-melanoma skin, cervical/breast in-situ carcinoma) but those fully recovered from an episode of cancer (in remission for more than 5 years) may be included at the discretion of the patient's treating rheumatologist.
• Persons with an active severe or serious infection
• Patients with non-severe infection at the discretion of the Investigator
• Persons with other concomitant disorders incompatible with study (at discretion of Investigator).

Where it is running

• University of California San Diego — La Jolla, California, United States
• Seattle Rheumatology Associates — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.